Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Comp Med ; 53(1): 70-4, 2003 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-12625509

RESUMEN

Genetics plays a substantial role in host resistance in many host-parasite interactions. We examined the prevalence of naturally acquired infection with Syphacia obvelata in a number of mouse strains housed in a non-barrier facility. These mice, which included cross-bred and congenic, inbred strains on various genetic backgrounds, differ in the loci for the immune function genes--major histocompatibility complex class II (MHCII), toll-like receptor 4 (Tlr4), and solute carrier family 11, member 1 (Slc11a1)--which allowed comparisons of the impact of these genes on resistance to pinworm infection. Male and female mice of various ages were sampled over an 18-month period; infection was determined by use of the cellophane tape test. Results indicated that mice that were MHCII+/+ had a significantly lower prevalence of infection than did mice that were MHCII-/-. Differences were not seen between male and female mice. Although MHCII+/+ mice had an age-associated decrease in infection prevalence, such decrease was not seen in MHCII-/- mice. In contrast, infection prevalence in mice with the normal Tlr4 gene (Tlr4(LPS-n/LPS-n)) gene did not differ significantly compared with that in mice that were homozygous for either the point mutation (Tlr4(LPS-d/LPS-d)) or deletion (Tlr4(LPS-del/LPS-del)) of that gene. Likewise, the presence (Sle11a1r/r) or absence (Slc11a1s/s) of functional alleles for Slc11a1 had no effect on the prevalence of infection with S. obvelata. In conclusion, presence of MHCII, but not Tlr4 or Slc11a1 significantly influences prevalence of naturally acquired infection with S. obvelata. These data justify further comprehensive analyses of the immune components that are involved in pinworm resistance.


Asunto(s)
Antígenos de Histocompatibilidad Clase II/fisiología , Inmunidad Innata , Oxiuriasis/inmunología , Animales , Ratones , Ratones Endogámicos C3H , Ratones Endogámicos C57BL , Especificidad de la Especie
2.
J Am Vet Med Assoc ; 220(3): 330-3, 2002 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-11829263

RESUMEN

OBJECTIVE: To determine efficacy of treatment with a combination febantel-praziquantel-pyrantel product, with or without vaccination with a commercial Giardia vaccine, in dogs with naturally occurring giardiasis. DESIGN: Prospective trial. ANIMALS: 16 Beagles naturally infected with Giardia duodenalis. PROCEDURES: During phase 1, 6 dogs were treated with the parasiticide for 3 days (4 were also vaccinated). Four weeks later, all 6 dogs were treated with the parasiticide again for 5 days and were bathed and moved to clean cages after the last treatment (phase 2). Nine dogs were treated with the parasiticide for 3 (n = 4) or 5 (5) days and bathed and moved to clean cages after the last treatment (phase 3). Fecal samples were collected twice weekly for 24 days after treatment and tested for cysts with a quantitative zinc sulfate flotation technique and for Giardia antigen with an immunoassay. RESULTS: Dogs in phase 1 were all shedding cysts again by day 24. In phase 2, only 1 dog shed cysts after treatment, and shedding was transient (day 17). In phase 3, neither cysts nor antigen was detected in fecal samples from 2 of 4 dogs treated for 3 days and 4 of 5 dogs treated for 5 days. In 18 of 57 (31.6%) fecal samples, cysts were seen, but results of the immunoassay were negative. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that when a combination febantel-praziquantel-pyrantel product is used to treat dogs with giardiasis, bathing and changing the environment after treatment may be more important in preventing recurrence than duration of treatment.


Asunto(s)
Antihelmínticos/uso terapéutico , Enfermedades de los Perros/tratamiento farmacológico , Giardiasis/veterinaria , Guanidinas/uso terapéutico , Praziquantel/uso terapéutico , Pirantel/uso terapéutico , Animales , Antihelmínticos/farmacología , Antígenos de Protozoos/análisis , Enfermedades de los Perros/parasitología , Enfermedades de los Perros/prevención & control , Perros , Combinación de Medicamentos , Heces/parasitología , Femenino , Giardia/efectos de los fármacos , Giardia/crecimiento & desarrollo , Giardia/inmunología , Giardiasis/tratamiento farmacológico , Giardiasis/prevención & control , Guanidinas/farmacología , Higiene , Masculino , Praziquantel/farmacología , Estudios Prospectivos , Vacunas Antiprotozoos , Pirantel/farmacología , Prevención Secundaria , Comprimidos , Resultado del Tratamiento , Vacunación/veterinaria
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA